In addition, inhibiting the CAMK2/CREB1 pathway resensitized MDR ovarian cancer cells to not only doxorubicin but also paclitaxel and topotecan, which are clinically employed to treat ovarian cancer (48). The gene discussed is CREB1; the disease is ovarian cancer.